Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Sierra Oncology, Inc. SRRA NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • CA • USD

SharesGrow Score
40/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Sierra Oncology, Inc. (SRRA) is a Biotechnology company in the Healthcare sector, currently trading at $54.99. It has a SharesGrow Score of 38/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Net income is $95M (loss), growing at -24.7%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $853,000 against $96M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 8.34 (strong liquidity). Debt-to-assets is 0.8%. Total assets: $109M.

Analyst outlook: 3 / 6 analysts rate SRRA as buy (50%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future 40/100 (Partial), Income ?/100 (Fail).

SRRA SharesGrow Score Overview

50/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 40/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SRRA

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
SRRA: -100%/yr revenue is, -24.7%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet SRRA: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 8.34 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
SRRA: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
40/100
Analyst outlook: 3 / 6 analysts rate SRRA as buy (50%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range54.98-55.01
Avg Volume (30D)651.46K
Beta (1Y)0.02
Share Statistics
EPS (TTM)-7.14
Shares Outstanding$13.25M
IPO Date2015-07-16
Employees109
CEONicholas Glover
Financial Highlights & Ratios
EBITDA$-94.36M
Net Income$-94.66M
Operating Income$-94.66M
Total Cash$104.75M
Total Debt$853K
Net Debt$-103.9M
Total Assets$109.37M
Price / Earnings (P/E)-7.7
Analyst Forecast
Rating ConsensusBuy
Analysts Covering6
Buy 50% Hold 50% Sell 0%
Company Info
CountryCA
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS82640U4040

Price Chart

Track all markets on TradingView
SRRA
Sierra Oncology, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
54.98 52WK RANGE 55.01

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message